MedPath

Efficacy and safety of budesonide /formeterol inhalation in asthma patients with high fractional exhaled NO.

Not Applicable
Conditions
Bronchial asthma
Registration Number
JPRN-UMIN000003735
Lead Sponsor
Komaki City Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1) have hypersensitivity with budesonide 2) have any severe complications 3) use of oral corticosteroids or systemic rescue medication 4) physician decided the patient is unsuitable for enrollment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Pulmonary function levels at 0, 4, 12 weeks. Fractional exhaled nitric oxide levels at 0, 4, 12 weeks. Values of impulse oscillometry at 0, 4, 12 weeks Adverse events
Secondary Outcome Measures
NameTimeMethod
Exacerbations during 12weeks
© Copyright 2025. All Rights Reserved by MedPath